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Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging coronavirus
causing respiratory disease commonly known as COVID-19. This novel coronavirus transmits from
human to human and has caused profound morbidity and mortality worldwide leading to the ongoing
pandemic. Moreover, disease severity differs considerably from individual to individual. Investigating
the virology of COVID-19 and immunological pathways underlying its clinical manifestations will
enable the identification and design of effective vaccines and potential therapies. In this review,
we explore COVID-19 virology, the contribution of the immune system (innate and adaptive) during
infection and control of the virus. Finally, we highlight vaccine development and implications of
immune system modulation for potential therapeutic interventions to design better therapeutic
strategies to guide future cure.
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1. Introduction
In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported to
have emerged in China, resulting in an unprecedented public health crisis. SARS-CoV-2 is the
seventh identified human coronavirus, thought to have spilled over from bats into humans through an
unknown intermediate [1,2]. Before the emergence of SARS-CoV-2, six human CoVs had been identified
of which two are life threatening, SARS-CoV and Middle East respiratory syndrome coronavirus
(MERS-CoV). SARS-CoV emerged in 2002 in China and ten years later, MERS-CoV was identified
in the Middle East [3–5]. Currently, a third novel pathogenic CoV (2019-nCoV or SARS-CoV-2) has
emerged, developing into a world public health emergency [6,7]. The name of this new emergent CoV
reflects its high phylogenetic similarity to SARS-CoV [8]. SARS-CoV-2 causes coronavirus disease
2019 (COVID-19) and it was declared a pandemic viral outbreak by the World Health Organization
(WHO) in March 2020 [9]. As of 26 July 2020, this pandemic has globally caused around ~15.5 million
confirmed cases leading to around ~650,000 deaths to date [10]. Most patients exhibit mild to moderate
symptoms but approximately 15–18% patients develop acute respiratory distress syndrome (ARDS),
cytokine storm and/or multiple organ failure [11].
2. Coronaviruses, Origin and Genome Structure
SARS-CoV-2 belongs to the subgenus Sarbecovirus of the beta coronavirus genus, and subfamily
Orthocoronavirinae of the Coronaviridae family [12]. It was recognized for the first time in December 2019
in Wuhan, a central city in China. There are four common human CoVs with low pathogenicity,
resulting in mild diseases; two alpha-CoVs (229E and NL63) and two beta-CoVs (OC43 and HKU1) [1].
The previous pathogenic CoVs, SARS-CoVs and MERS-CoVs caused severe and potentially fatal
respiratory tract infection in human populations [13]. SARS-CoV-2 belongs to beta-CoVs, which includes
SARS- and MERS-related CoVs [14,15]. Like other CoVs, SARS-CoV-2 is an enveloped spherical
particle (60–140 nm) with spike proteins on the surface (corona) (Figure 1) [12,14].
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Figure 1.
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The SARS-CoV-2 genome has 96.2% sequence identity to the bat CoV RaTG13 and it is 79.5%
identical to SARS-CoV. Accordingly, bats are considered the natural host and a potential origin of
the virus, and it may have transmitted to humans through an unknown intermediate [11,16] or
directly from the wet wild animal market in Wuhan. SARS-CoV-2 is an enveloped virus with a
single-stranded, positive-sense RNA genome (~30,000 nucleotides) having a 50 cap structure and 30
poly-A tail. It encodes several open reading frames (ORFs) [11,17–21]. Two-thirds of viral genome,
mainly located in the first ORF (ORF1a/b), translates two polyproteins, pp1a and pp1ab, composed
of 16 non-structural proteins (NSP1-NSP16), while the remaining ORFs, which are located near the
30 - terminus, encode accessory and structural proteins (Figure 2) [22,23]. The four main structural
proteins are envelope protein (E), nucleocapsid protein (N), membrane protein (M) and spike (S)
surface proteins [24–26]. The trimeric S protein, a type-I transmembrane glycoprotein on the surface
of the virus that forms the corona, is composed of two domains, the amino (S1) and carboxy (S2)
termini [25]. The two domains of S1 subunit, N-terminal domain “S1-NTD” and C-terminal domain
Figure 1. Coronavirus structure showing the organization of spike (S), membrane (M), and envelope
“S1-CTD” compose receptor-binding domains (RBD) (Figure 1), determine the virus–host range and
(E) proteins. The viral RNA is associated with the nucleocapsid protein (N). ACE: angiotensin
cellular tropism. The S2 subunit contains heptad repeat 1 (HR1) and heptad repeat 2 (HR2) domains,
converting enzyme; RBD: receptor-binding domains; S1-NTD: N-terminal domain; S1-CTD: Cwhich mediate the virus–cell membrane fusion [27–29].
terminal domain; S1: amino termini; S2: carboxy termini.
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3. Replication and Pathogenesis
3. Replication and Pathogenesis
The first step of CoVs replication is recognition and binding to host cell receptors via S1 subunit
(Figure 3). SARS-CoV-2 binds to the same cellular entry receptor angiotensin converting enzyme 2
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The first step of CoVs replication is recognition and binding to host cell receptors via S1 subunit
(Figure 3). SARS-CoV-2 binds to the same cellular entry receptor angiotensin converting enzyme 2
(ACE2) as SARS-CoV [16]. After binding with the ACE2 receptor, proteolytic cleavage of S protein
(ACE2) as SARS-CoV [16]. After binding with the ACE2 receptor, proteolytic cleavage of S protein
occurs within the S2 domains by transmembrane protease serine 2 (TMPRRS2), or cathepsin, resulting
occurs within the S2 domains by transmembrane protease serine 2 (TMPRRS2), or cathepsin,
in the virion membrane fusion with the host cell membrane [24]. This fusion releases the viral RNA into
resulting in the virion membrane fusion with the host cell membrane [24]. This fusion releases the
the host cytosol where translation of the two polyproteins, pp1a and pp1ab, begins and sixteen proteins
viral RNA into the host cytosol where translation of the two polyproteins, pp1a and pp1ab, begins
are cleaved out of these proteins by various viral and host proteases releasing the non-structural
and sixteen proteins are cleaved out of these proteins by various viral and host proteases releasing
proteins. Most of these non-structural proteins assemble to form the viral replicase–transcriptase
the non-structural proteins. Most of these non-structural proteins assemble to form the viral
complex (RTC) in double-membrane vesicles for subsequent synthesis of the nested set of subgenomic
replicase–transcriptase complex (RTC) in double-membrane vesicles for subsequent synthesis of the
RNAs (sgRNAs), which encode structural and accessory proteins (Figure 3) [24,30]. Genomic and
nested set of subgenomic RNAs (sgRNAs), which encode structural and accessory proteins (Figure
sgRNAs are produced through negative-strand intermediates. The genomic RNA and virion N protein
3) [24,30]. Genomic and sgRNAs are produced through negative-strand intermediates. The genomic
along with the E, S and M proteins in the virion membrane are transported to ER-Golgi intermediate
RNA and virion N protein along with the E, S and M proteins in the virion membrane are transported
compartment (ERGIC) and assemble together to produce the virus particle. Finally, virus-containing
to ER-Golgi intermediate compartment (ERGIC) and assemble together to produce the virus particle.
vesicle fuses with the host cell membrane to be released by exocytosis [11,24]. Several therapeutic
Finally, virus-containing vesicle fuses with the host cell membrane to be released by exocytosis
targets have been identified in the viral replication steps as indicated in the Figure 3 and are being
[11,24]. Several therapeutic targets have been identified in the viral replication steps as indicated in
explored for possible antiviral drug control strategies.
the Figure 3 and are being explored for possible antiviral drug control strategies.
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The immune system is responsible for the resolution of COVID-19, however, overactivation of
the immune system against SARS-CoV-2 can result in a severe cytokine storm due to the release of
huge numbers of inflammatory factors such as IL-2, IL-6, IL-7, GM-CSF, IP10, MCP1, MIP1A, and
TNF-α [35,36]. This virus-induced cytokine storm may be a cause of organ dysfunction and damage [35].
Understanding key targets in suppressing hyper immune activation may help improve disease severity
and progression therefore representing a key avenue of exploration for possible treatment strategies.
4. Clinical Characterization
SARS-CoV-2 is associated with human-to-human transmission and is thought to spread by
sneezing and respiratory droplets formed by coughing and by direct fomite transmission [39].
Additionally, isolation of SARS-CoV-2 from blood and fecal swabs suggests multiple transmission
routes [40]. SARS-CoV-2 airborne transmission may be possible in specific conditions. Due to its
persistence in aerosol droplets, a viable and infectious form can be possible over longer periods of
time [41,42]. Once infection is established, the clinical spectrum of COVID-19 varies from asymptomatic
to multi-organ failure. The symptoms of mild disease include fever, cough, fatigue, dyspnea, headache
and sore throat but in severe cases, the disease worsens 5–10 days after onset of infection. The incubation
period for symptomatic mild patients, the time from exposure to symptom onset, is 4–5 days on
average [43–45]. Some patients may have gastrointestinal symptoms such as vomiting and diarrhea.
However, in severe cases, individuals with COVID-19 develop signs and symptoms of ARDS,
which requires mechanical ventilation [46]. Prediction of COVID-19 severity and diseases risk are
complicated. Routine bloodwork often finds low lymphocyte counts, high C-reactive Protein (CRP)
and lactate dehydrogenase (LDH) levels and a high ratio of platelet/lymphocyte, which is positively
correlated with the disease severity [47,48]. Thrombocytopenia is associated with incidence of
myocardial injury in COVID-19 and coagulation parameters predict severity independently of other
variables [49,50]. Moreover, prognostic immune biomarkers in COVID -19 patients were identified
with the disease severity. Peripheral blood analysis demonstrates significantly lower counts of CD4+ T,
CD8+ T, and NK cells in PBMCs and increased expression of Programmed cell death protein 1 (PD-1)
and Tim-3 on T cells and has been correlated with severity of COVID-19. There is likely initial delay in
the antiviral response and subsequent increased production of inflammatory cytokines with an influx
of monocytes and neutrophils into the lung, leading to the cytokine storm syndrome [44]. There are
also phenotypic changes in peripheral blood monocytes with a distinct population which secrete
IL-6, IL-10, and TNF-α. IL-4, IL-6, IL-8, IL-10, IL-18, IL-2, IFN-γ, IL-2R and IL-1β along with other
cytokines showing a correlation with disease severity. CD14+CD16+GM-CSF+ monocytes are higher
in COVID-19 patients than healthy and GM-CSF+IFN-γ+ T cells are higher in ICU patients than in
non-ICU patients [51]. Single-cell RNA-seq analysis in early-recovery patients has identified abundant
CD14+IL-1β+ monocytes, thought to be associated with the cytokine storm [52]. T cell counts and
cytokine levels (Figure 4) in severe COVID-19 patients who survive the disease gradually recover at
later time points to levels which are comparable to mild infection. As all patients are lymphopenic,
the neutrophil-to-CD8+ T cell ratio, counts of CD4 and CD8 T cells, and cytokine IL-6 and IL-10 can be
identified as the most powerful prognostic factors for the progression of disease from mild to severe
CoV-2 infection [53]. Additionally, computed tomography on the chest shows ground-glass opacity
and bilateral patchy shadows [54].

Vaccines 2020, 8, 443

Vaccines 2020, 8, x

6 of 21

6 of 21

Figure4.4.Immune
Immunedysregulation
dysregulationmechanisms
mechanismsduring
duringcoronavirus
coronavirus
disease
2019
(COVID-19).
Figure
disease
2019
(COVID-19).

5.5.Innate
InnateImmunity
Immunityduring
duringCOVID-19
COVID-19
The
Theinnate
innateimmune
immunesystem
systemofofthe
thehost
hostisisthe
thefirst
firsttotoreact
reactwith
withthe
theviral
viralinfections
infectionshelping
helpingtoto
detect
detectand
andcontrol
controlthem.
them.This
Thisdetection
detectionisisachieved
achievedby
byusing
usingpattern
patternrecognition
recognitionreceptors
receptors(PRRs)
(PRRs)
such
as
toll-like
receptors
(TLRs),
NOD-like
receptors
(NLRs),
RIG-I-like
receptors
(RLRs)
such as toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-I-like receptors (RLRs)and
andC-type
C-type
lectin-like
[55,56].
PPRs
recognize
pathogen-associated
molecular
patterns
(PAMPs)
suchsuch
as
lectin-likereceptors
receptors
[55,56].
PPRs
recognize
pathogen-associated
molecular
patterns
(PAMPs)
lipo-proteins,
lipids,
nucleic
acids,
andand
proteins
of viral
origin
in in
thethe
host
cell
membranes
including
as lipo-proteins,
lipids,
nucleic
acids,
proteins
of viral
origin
host
cell
membranes
including
lysosomes
and
endosomes.
Upon
recognition,
different
biological
responses
are
induced
through
lysosomes and endosomes. Upon recognition, different biological responses are induced through
the
the
activation
of varied
adapter
proteins
leading
to release
the release
of pro-inflammatory
cytokines
that
activation
of varied
adapter
proteins
leading
to the
of pro-inflammatory
cytokines
that recruit
recruit
immune
of infection
viral replication
and activate
the
other other
immune
cells tocells
the to
sitethe
of site
infection
[57,58],[57,58],
inhibit inhibit
viral replication
and activate
the adaptive
adaptive
immune
response
by
pathogen-derived
antigen
presentation
via
activated
dendritic
cells
immune response by pathogen-derived antigen presentation via activated dendritic cells (DCs) to
(DCs)
naïve Thelper
cells. Natural
killer
cells kill
(NKs)
the infected
cells through
mechanisms
naïvetohelper
cells. TNatural
killer cells
(NKs)
thekill
infected
cells through
mechanisms
such as
such
as
degranulation,
antibody-dependent
cellular
cytotoxicity
and
receptor
mediated
degranulation, antibody-dependent cellular cytotoxicity and receptor mediated apoptosis.
apoptosis.
Macrophages
eliminate the
thepathogen
pathogenand
and
infected
cells
through
phagocytosis.
Macrophagesand
and neutrophils
neutrophils eliminate
infected
cells
through
phagocytosis.
Even
Even
though
all
these
mechanisms
are
important
for
viral
elimination,
an
over-reactive
immune
though all these mechanisms are important for viral elimination, an over-reactive immune response
response
may contribute
to disease
pathogenesis
may contribute
to disease
pathogenesis
[59–61].[59–61].
There
is
compelling
evidence
for
innate
There is compelling evidence for innateimmune
immunehyperactivity
hyperactivityduring
duringacute
acutelung
lunginjury
injurythat
thatisisa a
hallmark
infections.
hallmarkofofSARS-CoV-2
SARS-CoV-2
infections.Reduced
Reducedblood
bloodlymphocytes
lymphocytesand
andhigher
higherneutrophil
neutrophilcounts
countsare
area a
hallmark
of
SARS-CoV-2.
Neutrophils
are
recruited
at
the
site
of
infection
where
they
kill
pathogens
hallmark of SARS-CoV-2. Neutrophils are recruited at the site of infection where they kill pathogens
bybyoxidative
oxidativeburst
burstand
andformation
formationofofneutrophils
neutrophilsextracellular
extracellulartraps
traps(NETs)
(NETs)[62].
[62].SARS-CoV-2
SARS-CoV-2infection
infection
and
lung
cell
destruction
trigger
a
local
immune
response
by
recruiting
macrophages
and
monocytes
and lung cell destruction trigger a local immune response by recruiting macrophages and monocytes
that
thatrelease
releasecytokines
cytokinesand
andprime
primeadaptive
adaptiveimmune
immuneresponse
response[63].
[63].AAdysfunctional
dysfunctionalimmune
immuneresponse
response
can
cause
severe
lung
and
systemic
pathology
inducing
injury
and
death
of
virus
infected
cells
can cause severe lung and systemic pathology inducing injury and death of virus infected cellsand
and
tissues.
macrophages
are involved
in the epithelial
damage during
the during
acute respiratory
tissues.Tissue-resident
Tissue-resident
macrophages
are involved
in the epithelial
damage
the acute
distress
syndrome
[64].
respiratory
distress
syndrome [64].
Macrophages
are
Macrophages areactivated
activatedafter
afterdetecting
detectingthe
thePAMPs
PAMPsininviral
viralRNA
RNAbybytheir
theirpattern
patternrecognition
recognition
receptor
as
well
as
damage
associated
molecular
patterns
(DAMPs)
including
receptor as well as damage associated molecular patterns (DAMPs) includingATP,
ATP,DNA
DNAand
and
antibody-secreting
cellcell
(ASC)
protein
oligomers
[60,65].[60,65].
These DAMPs
and PAMPs
likely generated
antibody-secreting
(ASC)
protein
oligomers
These DAMPs
andarePAMPs
are likely
during
SARS-CoV-2
infection leading
to lysis
of pneumocytes,
resulting in a wave
of local
generated
during SARS-CoV-2
infection
leading
to lysis of pneumocytes,
resulting
in ainflammation
wave of local
and
secretion
of
proinflammatory
cytokines
including
IL-6,
IL-1β
and
IFN-γ
as
well
the IFN-γ
chemokines
inflammation and secretion of proinflammatory cytokines including IL-6, IL-1β and
as well
IP10
and
MCP1
into
the
blood
of
infected
patients
[34]
leading
to
other
cytokine
production
and
the chemokines IP10 and MCP1 into the blood of infected patients [34] leading to other cytokine

production and antiviral gene activation, especially interferon-stimulated genes uniquely
upregulated in NK cells. The inflammatory cascade triggered by macrophages leads to viral control,
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antiviral gene activation, especially interferon-stimulated genes uniquely upregulated in NK cells.
The inflammatory cascade triggered by macrophages leads to viral control, through production of
interferon I and III, thereby promoting antiviral defenses in neighboring epithelial cells, and tissue
damage. The secretion of cytokines, mainly IL-6 and IL-1β, also promotes the recruitment of other
immune cells, mainly monocytes and T lymphocytes, to the infection sites. Such infiltration of
lymphocytes to the infected airways might explain the lymphopenia in the majority of SARS-CoV-2
infected patients [54,66]. Recent studies have shown elevated IL-6 levels in COVID-19 non-survivors
compared to survivors [33]. Increased inflammatory monocyte-derived FCN1+ macrophages have been
observed in bronchioalveolar lavage fluid from severely ill patients compared with mild COVID-19
patients. Similarly, an increased population of CD14+CD16+ inflammatory monocytes cells have been
observed in severely diseased patients indicating a significant contribution of innate immune cells
in COVID-19 disease [67]. Wilk et al. reported that in CD14+ monocytes, human leukocyte antigen
(HLA) class II expressions, as well as a pathway associated with DC–NK cell immune crosstalk, were
reduced, whereas a pathway associated with PD1–PDL1 interactions was increased. Collectively,
these results indicate that dysregulation of immune crosstalk is associated with severity of COVID-19.
Furthermore, a functional exhaustion of natural killer (NK) cells and cytotoxic T cells (CTLs), which are
required for an effective antiviral immune response, enhances disease progress [67]. This exhaustion is
believed to be triggered by the overexpression of a prominent heterodimeric NK inhibitory receptor,
namely, NK group-2 member A (NKG2A) that is overexpressed in CD8+ and NK cells [68]. NKG2A
transduces inhibitory signals on ligation with peptide loaded HLA-E thereby suppressing cytokine
secretion by NK and its cytotoxicity. This results in overriding the innate immune response of the host
by SARS-CoV-2 and also increases the opportunities of co-infections of the lung in patients with severe
symptoms [69].
6. Adaptive Immunity during COVID-19
6.1. T Cell Immune Response to SARS-CoV-2 Infection
T lymphocytes, CD4+ T cells and CD8+ T cells, play a vital role in balancing their antiviral activity
with the possibility of developing an excessive immune inflammatory response or autoimmunity [70–72].
While CD8+ T cells help in direct elimination of virally infected cells through cytotoxicity, CD4+ T
cells are vital for stimulating CD8+ T cells and B cells. In SARS-CoV-2 infection, it is uncertain if the
adaptive immune response is helpful or harmful in combating the condition. A late T cell response
may contribute towards worsening the disease condition through amplification of the pathogenic
inflammatory response in the presence of huge viral loads in the lungs [73]. Furthermore, previous
studies on SARS-CoV infections have indicated that at the time of infection, a depletion in CD8+ T cells
does not affect or delay the viral replication. However, depletion in CD4+ T cells during the infection
results in a delayed viral clearance accompanied by strong immune-mediated interstitial pneumonia
that is triggered by reduced neutralizing antibodies, recruitment of pulmonary lymphocytes and
cytokine production [74]. Moreover, monocytes and neutrophils are recruited to the site of infection by
the IL-17 released by T helper cells, which further exacerbates the condition via release of downstream
cytokines and chemokines, such as TNFα, MCP-1, IL-6, IL-1, IL-8 and IL-21 [60].
Studies on autopsy and blood samples of COVID-19 patients have revealed that the peripheral
blood contains a low number of hyperactive T lymphocytes. Most of the T lymphocytes had
accumulated in the lungs, suggesting an infiltration of T cells from blood to the site of infection [45].
The SARS-CoV-2 patients exhibit a Th1 mediated immune response where TNF, INF-γ and IL-2 are
expressed by SARS-CoV-2 specific CD4+ T cells aiding in disease control by cell mediated immunity.
A study in a mouse model, immunized with dendritic cells bearing SARS-CoV peptides resulted
in the accumulation of large numbers of virus specific CD4+ and CD8+ T cells in the lungs [75].
This finding supported the possibility that the delay in T cell response during infection might be due
to the lack of availability or function of antigen presenting cells (APCs). However, even though T cell
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responses controlled SARS-CoV infections, several protein vaccine formulations tested so far have
resulted in immunopathological reactions, especially in aged animals via a Th2 mediated eosinophil
infiltration [63]. Hence, more studies are required to understand the protective versus pathological T
cell responses for vaccine formulations.
6.2. Role of Memory T Cell against SARS-CoV-2
Recent studies have investigated the existence of SARS-CoV-2 specific memory T cells [76,77] and
SARS-CoV-2 specific CD4+ and CD8+ T cells, which were present in 80% of patients admitted to the
ICU. The CD4+ T cells were predominately Th1 cells. Interestingly, 20% of the control subjects also
showed SARS-CoV-2 specific T cells. The reactivity of the T cells in the patients and the controls was
directed mainly toward the spike glycoprotein [78]. The researchers point out that there should be
cross reactivity between common cold coronavirus and SARS-CoV-2 due to presence of memory T
cells in uninfected individuals [78,79]. Another study showed that CD4+ T cells were found in 100%
of the convalescent patients while CD8+ T cells were found only in 70% of the convalescent patients.
The CD4+ T cells were reactive toward M, spike, and N proteins, which are different from SARS-CoV-1
where memory CD4+ T cells were reactive mainly toward spike protein. This difference could be
important for SARS-CoV-2 vaccine development. Incorporation of SARS-CoV-2 structural antigens in
addition to the spike protein might better mimic the efficient immune response in COVID-19 patients
showing mild and moderate disease course. Similarly, an efficient vaccine that relies on eliciting CD8+
T cell response towards SARS-CoV-2 should make use of HLA class I epitopes derived from the M,
nsp6, ORF3a, and/or N proteins [73].
6.3. B Cell Immunity during SARS-CoV-2 Infection
The B lymphocytes in the blood are involved in early effect or responses via producing protective
antibodies in response to the initial challenge, as well as in initiating the production of memory
cells to provide comprehensive immunity against repeated infection [80]. The B cell response to an
infection, virus or vaccination, generates virus antigen-specific antibodies (Abs) that play a key role in
providing a protective barrier to infection and in facilitating viral clearance. Both antibody-secreting
cells (ASCs) and memory B cells are the product of antigen activation. Interaction of B cells with
cognate T helper cells is the critical requirement in most cases for optimal antibody responses. This T
cell help is important for directing antibody isotype switching in B cells, the process by which B cells
switch from expressing IgM to expressing alternative isotypes IgGs and IgA with different functional
characteristics [81]. ASCs can be divided into short-lived ASCs, including short-lived plasma cells,
plasmablasts, and long-lived plasma cells. Plasmablasts are considered a transient population and
can be either precursors of plasma cells (short- and/or long-lived; mainly in mice) or terminally
differentiated effector cells. One of the hallmarks of the immune system is the memory of past exposure
to infections (antigens). Thus, the success of vaccines is dependent on the generation and maintenance
of long-term immunological memory.
There is great interest in understanding the B cell memory humoral responses to SARS-CoV-2
infection, which has been studied in the context of antibody distribution in the peripheral blood of
COVID-19 patients. However, little has been attempted to evaluate immunophenotyping of B cells
in patients with different clinical courses of COVID-19. Comparing CD45+ hematopoietic cells from
22 healthy controls and 17 COVID-19 patients, the authors found an expansion of CD19+ B cells in
COVID-19 patients with a significant increase in CD138+ ASCs among other B cell subpopulations:
transitional, naive, double-negative (DN), and memory [82]. Interestingly, a greater abundance of these
mature, CD138+ ASCs, which are often associated with protection during a vaccine-induced response,
were found in COVID-19 patients with worse outcomes [82]. Previously, Jenks et al. described an
IgD-CD27-double negative B cell population in flaring systemic lupus erythematosus (SLE) patients
characterized as part of an extra-follicular (EF) response [83], which is also elevated in rheumatoid
arthritis patients [84]. EF B cell activation is particularly prominent in African American SLE patients,
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a population disproportionately affected in severe COVID-19. In SLE, the EF pathway of activating
naïve B cells leads to a large expansion of autoantibodies-ASCs through the primed B cell precursor
which is double-negative for naive (IgD) and memory markers (CD27), as well as lacking the expression
of CXCR5 and CD21. The Preprint data support DN cells which lack CXCR5 and CD21 expressions
suggesting that the global EF pathway could be prominently engaged in COVID-19 patients [82].
Understanding the role of pathogenic B cells could be crucial for designing immuno-modulatory
therapies that target pro-inflammatory or potentially autoimmune phenotypes seen with SARS-CoV-2
infections. Thus, this B cell phenotype might serve as an immunological biomarker for severe
SARS-CoV-2 infection at early stages.
6.4. B Cell Responses
The kinetics of the antibody response to SARS-CoV-2 are currently elucidated as robust B cell
responses. There is an urgent need for both sensitive and specific SARS-CoV-2 serological testing to not
only reliably identify all infected individuals regardless of clinical symptoms, but also to determine the
percentage of convalescent individuals in the population. Multiple serological assays have been used to
characterize antibody responses to coronaviruses. The most commonly used assays are called antibody
(Ab) assays, which use binding assays, including enzyme linked immunosorbent assays (ELISA),
immunofluorescence assays (IFA), Western blots, hemagglutination inhibition (HAI), complement
fixation (CF), and neutralization. Antibodies binding the SARS-CoV-2 internal N protein and the
external S glycoprotein are commonly detected. Neutralization assays are considered the gold standard
for measuring functional antibody responses by IgG, IgM and IgA [85,86]. Similar to SARS-CoV-1
infection, CoV-2 Abs are found in most COVID-19 patients [87]. IgM and then IgG appeared with a
median time of 12 and 14 days, respectively. After 8 days, the sensitivity of the Ab assay was higher
and reached up to 90% at day 13 and at a later time point, after 15 days, reached 100%, with antibody
titers persisting in the weeks following virus clearance [88,89]. There was a strong positive correlation
between clinical severity and antibody titer from 2 weeks after illness onset. The high virus-specific
antibody titers to SARS-CoV-2 correlated with in-vitro neutralization of the virus and decline in the
viral load in patients [90]. The total serum IgM and IgG can be used to determine the level of humoral
immune response in COVID-19 patients [50,91].
Antibodies binding to the RBD can be potently neutralizing (nAbs), preventing it from binding
to the host entry receptor, ACE2 [89,92]. Anti-RBD nAbs are detected in most COVID-19 patients
but no cross reactivity was found to the RBD from SARS-CoV-1 or MERS-CoV and plasma from
COVID-19 patients did not neutralize SARS-CoV-1 or MERS-CoV [50,92]. Sequences from single cell
sorted RBD-specific CD19+IgG+ memory B cells showed a diverse repertoire with low or no somatic
hypermutation. Premkumar et al. generated the recombinant RBDs of SARS-CoV-1, SARS-CoV-2 and
human endemic coronaviruses (hCoV HKU-1, OC-43, NL63 and 229E). Their data corroborate previous
reports and observations about enhanced specificity of the SARS-CoV-2 induced Abs to its RBD over
the RBDs of other CoVs. This suggests pre-existing binding Abs against endemic human coronaviruses
seem not to cross-react with the SARS-CoV-2 RBD and that titers of anti-RBD binding Abs robustly
correlate with nAb levels [93]. Together, these results make obvious that there is virus-specific antibody
mediated neutralization and it is driven by binding to epitopes within the RBD. Clearly understanding
the antibody responses against SARS-CoV2 is useful in the development of serological tests for the
diagnosis of COVID-19 [90].
7. Therapeutics
So far, no specific treatment is available for COVID-19 and only symptomatic and supportive
treatments are being pursued [3,6]. The main target is control of the disease manifestation using
available drugs. Studies to find the best therapeutic approach for the disease and its management
continue to increase. The most common therapeutic options for viral infections are either blocking
viral entry and replication or promoting immunity of the uninfected population through vaccination.
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Therefore, the development of effective vaccines and specific antiviral treatments are the main concern
of scientists worldwide [14,94–101]. The genome sequence of SARS-CoV-2 was rapidly characterized,
enabling researchers to design vaccines and antiviral drugs, isolate neutralizing monoclonal antibodies
and use convalescent plasma as therapy.
8. Vaccine Development
Since the emergence of SARS-CoV in 2002, several vaccine approaches have been reported but
none has been approved yet by the FDA. During the ongoing SARS-CoV-2 pandemic, unprecedented
efforts are being made in vaccine development. Just six months into the pandemic, more than 100
potential vaccines are already into different phases of preclinical or clinical trials. Vaccine design
has mainly exploited the viral spike protein to induce anti-viral immunity. Several different vaccine
platforms are being evaluated, such as whole virus (attenuated or inactivated) [102–104], virus-vectored
plasmid encoded viral antigens [94,105] and viral proteins [106–110].
Currently, many institutions and companies are involved in developing SARS-CoV-2 vaccines.
On July 2020, several vaccine candidates were included by the global COVID-19 vaccine
R&D landscape (for review, [111,112]). Some of the most promising candidate clinical trials
were PiCoVacc from Sinovac Biotech (Beijing, China) (NCT04456595), INO-4800 from Inovio
(San Diego, CA, USA) (NCT04447781) [113], Ad5-nCoV from CanSino Biologics (Tianjin, China)
(NCT04313127) [114], mRNA-1273 from Moderna (Cambridge, MA, USA) (NCT04299724) [115],
LV-SMENP-DC (NCT04299724) and pathogen-specific aAPC (NCT04276896) from Shenzhen Medical
Institute. Additionally, several inactivated vaccine candidates for SARS-CoV-2 have been developed
by different companies such as Wuhan Institute of Biological Products (Sinopharm, Wuhan, China),
Beijing Institute of Biological Products (Sinopharm), Bharat Biotech (Hyderabad, India) and Medical
Biology, Chinese Academy of Medical Sciences. Their vaccines are currently under clinical trials [112].
Sinovac Biotech developed a purified inactivated vaccine candidate for SARS-CoV-2 (PiCoVacc)
(Figure 5) [116]. In macaques, this vaccine triggered specific neutralizing antibodies and complete
protection at a dose of 6 µg without antibody-dependent enhancement (ADE) of infection.
These promising results encouraged transition to phase-1 clinical trials. DNA vaccine platforms
use plasmids encoding SARS-CoV-2 S protein. This type of vaccine is simple, safe and stable [117].
Inovio Pharma engineered a synthetic DNA vaccine targeting SARS-CoV-2 S protein (INO-4800)
similar to their prior vaccine candidate targeting the MERS-CoV S protein (Figure 5) [113]. INO-4800
induced functional antibodies and T cell responses that block SARS-CoV-2 S protein/ACE2 binding.
Additionally, CanSino Biologics developed a recombinant adenovirus type-5 (Ad5) vectored COVID-19
vaccine expressing the S protein of SARS-CoV-2 (Ad5-nCoV), which has been shown in a phase 1
trial to be well tolerated and immunogenic (Figure 5) [114]. Currently, it is in a phase II clinical
trial. Interestingly, Moderna has designed and developed mRNA-based vaccines encoding the viral S
protein (Figure 5) [115]. Their mRNA-1273 is encapsulated in bilipid nanoparticles (LNPs) and has
entered phase III clinical trial. Shenzhen Geno-Immune Medical Institute has two vaccine candidates,
which have entered phase I studies, LV-SMENP-DC and pathogen-specific aAPC. The LV-SMENP-DC
vaccine was formed by modifying dendritic cells (DCs) with lentivirus vectors expressing SMENP
(COVID-19 minigene) and immune modulatory genes. LV-DC presenting COVID-19 specific antigens
is activated by cytotoxic T lymphocytes (CTLs). COVID-19/aAPC vaccine is also formed from
lentivirus modifications with immune-modulatory genes and the viral minigenes to the artificial
antigen-presenting cells (aAPCs) [111,112].
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Figure 5. Clinical phase vaccine candidates for COVID-19.
Figure 5. Clinical phase vaccine candidates for COVID-19.
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antibody (Tocilizumab) is a humanized recombinant IgG1 monoclonal antibody that binds to the
soluble and membrane bound IL-6 receptor [130]. Increased IL-6 is a hallmark of COVID-19 patients
along with high levels of C reactive protein, therefore using Tocilizumab has been recommended after
effective results in treating such patients to manage cytokine release syndrome (CRS) [129]. Similarly
biologics that target IL-1 and IL-17 inflammatory cytokines can also be effectively used in treating
COVID-19 patients. IL-1R, GM-CSF, and the chemokine receptor CCR5, have also been proposed as
potential blockade targets to manage COVID-19 CRS [50].
11. Convalescent Plasma Therapy for COVID-19
Convalescent plasma (CP) may contain therapeutic levels of anti-SARS-CoV-2 neutralizing
antibodies, which would reduce subsequent rounds of viral replication and increase viral clearance
until we have a vaccine and specific monoclonal antibodies. Passive immunization with CP therapy
seems to be associated with improved outcomes and appears to be safe, however, safety and effectiveness
for CP transfusion needs to be studied more carefully [43]. Anticoagulant therapy has also been
suggested as COVID-19 patients have a higher incidence of venous thromboembolism [131].
12. Neutralizing Monoclonal Antibodies
Patients who have recovered from SARS-CoV-2 infection are one potential source of neutralizing
antibodies (nAbs) [50,92]. The 193-amino acid receptor-binding domain (RBD) of the spike protein is
the key target of neutralizing monoclonal antibodies. Single cell sequencing has been used to clone the
heavy and light chain variable regions to express recombinant antibodies from RBD-specific memory B
cells. Four of the antibodies produced in these studies (31B5, 32D4, P2C-2F6, P2C-1F11) showed high
neutralizing potential in vitro [50]. SARS-CoV-1 and SARS-CoV-2 share about 80% of their sequence
identity. Animal models have also been used to generate nAbs against SARS-CoV-2; Wang et al.
developed a fully human monoclonal antibody (47D11) in H2L2 mice that neutralizes SARS-CoV-2
(and SARS-CoV) in cell culture [132]. Many pharmaceutical companies are utilizing this approach
either as monoclonal or pooled set of nAbs to find a broad-spectrum antibody which is the needed for
the treatment until we have a vaccine to provide long-term immunity.
13. Cellular Therapy
Cellular therapy using NK cells and mesenchymal stem cells (MSCs) might be a therapeutic option.
NK cells are important immune cells necessary for antiviral defense [133]. They lyse antibody-coated
virus-infected cells via the process of antibody-dependent cellular cytotoxicity (ADCC) [134]. NK cell
therapy to enhance immunity is currently a very feasible strategy for the prevention or treatment of
COVID-19 pneumonia.
Another promising approach would be MSCs, which have strong anti-inflammatory and
immunomodulatory functions. Numerous studies have shown that treatment with MSCs can
ameliorate acute/chronic lung injury and ARDS by suppressing the infiltration of immune cells
to pulmonary tissues and pro-inflammatory cytokine secretion [135].
14. CRISPR/Cas Mediated Therapeutic Options of COVID-19
Diversity of human viral pathogens and their ability to adapt their environment rapidly requires a
flexible and rapidly programmable antiviral technique to control them. To this end, the genome editing
technique CRISPR/Cas9 could be a potent weapon against a diverse range of viral pathogens. It could
be used to treat diseases caused by viral pathogens by: (i). manipulating host immunity against the
pathogen, (ii). destroying the pathogen directly without using immune cells. CRISPR/Cas9 has already
been used successfully to reprogram B and T cells for immunotherapy of cancer patients [136] and
holds great promise in immunotherapy. Here, we shall shed light on the possibility of using this
technique to produce designer immune cells with antiviral activity and an option of using CRISPR to
fend off pathogens directly.
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15. Designer B and T Cells for Antiviral Activity
B cells are a vital component of adaptive immunity in humans and an attractive genome editing
target due to their unique function of antibody production in the body [137]. Moreover, easy
isolation and cultivation of primary B cells are additional advantages for genome modification for
subsequent immunotherapy of diseases [138]. Johnson et al. engineered primary B cells using
CRISPR/Cas9 protein to knockout endogenous CD19 genetically and its protein and also integrated a
splice acceptor-Enhanced Green Fluorescent Protein (EGFP) cassette into the Adeno-associated virus
(AAV) S1 locus using CRISPR/Cas9 protein in combination with AAV serotype 6 (AAV6), an efficient
DNA template donor [139]. Their research work indicates that the primary B cells can be engineered to
produce specific antibodies against a pathogen. After obtaining mature plasma cells from engineered
B cells in vitro, these cells can be reintroduced into the host for long-term high titer expression of
antibodies in serum against a specific antigen.
Toll-like receptors (TLRs) in B cells, which belong to the germ line-encoded pattern recognition
receptors (PRRs) family, are known to be the most important initiators of an antiviral response
upon infection [140]. Among different members of this receptor family, which recognizes different
pathogen-associated molecular patterns, TLR7 recognizes many RNA viruses including influenza A
virus (IAV) [141]. Moreover, TLR7-mediated humoral immune responses are found to be sufficient
in causing two virus strains, mouse mammary tumor virus (MMTV; a betaretrovirus) and murine
leukemia virus (MuLV; a gammaretrovirus), to be cleared from mice [142]. Combining the activation of
TLR7 with the Johnson et al. findings of producing specific antibodies against pathogens [139], B cells
engineered in CRISPR/Cas9, designer B cells against RNA based SARS-CoV-2 virus could be used as a
produced for immunotherapy of COVID-19 patients.
Another potent component of the immune system in the body is T cells, which have been
engineered using CRISPR/Cas9 for immunotherapy of cancer cells. CRISPR/Cas9 has been used to
generate chimeric antigen receptor (CAR) T cells. CAR T-cells are modified T cells that harbor a tumor
targeting receptor for a specific antigen on tumor cells. Tumor targeting receptor consists of two
components, i.e., an extracellular single chain variable fragment (ScFv) to recognize tumor antigen and
an intracellular chimeric signaling domain that activates T cells to kill tumor cells [143]. CAR T-cells
have been used successful for B cell malignancy therapy by targeting CD19 antigen expressed by
B-cells. Moreover, CAR T-cell based therapies are under evaluation in multiple clinical trials against
different solid tumor antigens such as Her2/neu, CEA, EGFR, interleukin-13 receptor alpha 2 (IL13Rα2),
MesothelincMet and GD2 [144]. Therefore, it may be possible to design T cell modifications using
CRISPR/Cas9 to produce CAR T-cells specific to ssRNA viral pathogens. A specific antigen receptor
for COVID-19 can be introduced in T-cells, which will make programmed T-cells more active, resistant
to inhibition and exhaustion against SARS-CoV-2 infection in contrast to normal T-cells, which would
reduce in number of infected cells during COVID-19 [45].
16. Diagnostic and Antiviral Potential of CRISPR/Cas13
CRISPR/Cas technology can not only be utilized for the programming of immune cells but for
direct antiviral activity as well. Interestingly, Freije et al. [145] demonstrated strong antiviral activity
of a CRISPR/Cas13 against three single stranded RNA viruses: influenza A virus (IAV), vesicular
stomatitis virus (VSV) and lymphocytic choriomeningitis virus (LCMV). They have detected several
Cas 13 (RNA targeting protein) crRNA target sites in hundreds of ssRNA viral species that normally
infect humans and developed a Cas13-based diagnostic and viral RNA destroying tool called CARVER
(Cas13-assisted restriction of viral expression and readout). Since CARVER is a reprogrammable
diagnostic and viral RNA targeting tool, it has unlimited potential for use in rapid diagnostics for
SARS-CoV-2 in human samples by synthesizing crRNA complementary to unique genomic regions of
this virus.
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17. Conclusions
The COVID-19 pandemic has drastically affected global healthcare systems and the worldwide
economy. It is the largest pandemic outbreak since the Spanish flu in 1918 and has forced changes in
the lifestyles of people in terms of more hygiene and restricted social interactions. Scientists around the
world are engaged in research towards finding an efficient disease treatment and vaccine to prevent
this fast-spreading disease. Several strategies are already being tried clinically to handle the infection,
but still there is a desperate need for effective treatments and vaccines against COVID-19. Multiple
potential vaccines have been developed and are in different phases of development with the hope of
having a successful vaccine by the end of 2020. Many antiviral drugs, such as remdesivir or lopinavir,
are currently used either alone or in combination for COVID-19 treatment in multiple clinical trials.
Immunomodulator drugs targeting cytokines are being used to control the cytokine storm. Several viral
and immunological parameters are being explored to identify a potential target for cure strategies.
Cellular, as well as humoral immune, responses are being targeted by potential vaccines. Consistently,
key steps in viral replication are being identified and exploited as pharmacological targets. Therefore,
a better understanding of virological, immunological, and clinical details would open avenues for
developing potent solutions.
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